Dengue Virus Entry as Target for Antiviral Therapy

Table 2

Overview of all described DENV entry inhibitors.

Class	Compound	Serotype*	Cell line	References
Fusion inhibitors	1OAN1	DENV-2	LLC-MK2	[49]
	DN59	DENV-2	LLC-MK2	[50]
	Compound 6	DENV-1-4	A549, BHK	[51]
	Tetracycline derivates	DENV-2	BHK	[52]
	Doxorubicin derivate	DENV-1, -2, -3	Vero, C6/36	[53]
	NITD448	DENV-2	BHK, C6/36	[54]
Glycosidase inhibitors	Castanospermine	DENV-1-4	BHK	[55, 56]
		DENV-2	Huh-7	[55]
	DNJ	DENV-1	Mouse neuro 2a cells	[56]
	NN-DNJ	DENV-2	BHK	[57]
	Alkylated iminocyclitol	DENV-2	BHK	[58]
	OSL-9511	DENV-2	BHK	[59]
	CM-9-78	DENV-2	BHK	[60]
CBAs	Con A, WGA	DENV-2	BHK	[43]
	HHA, GNA, UDA	DENV-1-4	Raji/DC-SIGN, MDDC	[61, 62]
		DENV-1-4	Huh-7, U87/DC-SIGN	Unpublished results
		DENV-1-4	Raji/L-SIGN, U87/L-SIGN	Unpublished results
	PRM-S	DENV-2	MDDC	[62]
Heparan mimetics	GAG	DENV-2	Vero	[28]
	Heparin	DENV-2	Vero	[28, 29]
		DENV-2	BHK	[43]
		DENV-2	Hepatocytes	[38]
	Suramin	DENV-2	Vero, BHK	[28, 63]
	PI-88	DENV-2	BHK and in mice	[63]
	PPS	DENV-2	BHK	[63]
	Fucoidan	DENV-2	BHK	[64]
	Sulfated galactomannan	DENV-1	C6/36	[65]
	DL-galactan	DENV-2, -3	Vero, HepG2	[66]
	Carrageenan	DENV-2, -3	Vero, HepG2	[66, 67]
	α-D-glucan	DENV-2	BHK	[68]
	Dextran sulfate 8000	DENV-2	Hepatocytes, Vero	[66]
	DS (MW > 500,000 Da)	DENV-2	Raji/DC-SIGN	[61]
	Zosteric acid	DENV-1-4	LLC-MK2	[69]

*Serotype: The serotype mentioned is the serotype that has been tested and found susceptible to inhibition by the compound. Non-mentioned serotypes were not tested or could not be inhibited by the compound.